OnabotulinumtoxinA for OAB in Practice

OnabotulinumtoxinA (onabotA) is among the most clinically nuanced options in the overactive bladder (OAB) therapeutic toolkit—a procedure-based intervention with a durable evidence base, meaningful dosing considerations, and a retreatment schedule that demands proactive systems support to sustain. In the fourth segment of this series, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES founder, Fosnight Center for Sexual Health in Asheville, North Carolina, provides a detailed review of how she approaches onabotA in practice, from the initial counseling conversation through long-term maintenance. Fosnight frames onabotA not as a single procedure but as a package that encompasses preprocedural evaluation, the injection itself, a 2-week follow-up visit, and a 3- to 4-month reassessment to assess durability and schedule the next injection—and she communicates this full scope to patients before they commit, ensuring that informed consent reflects the ongoing nature of the therapy.

On the question of dosing, Fosnight addresses a clinically significant misinterpretation in the field: the local coverage determination language establishing 100 U as the FDA-approved, on-label dose for non-neurogenic OAB is sometimes treated as an absolute ceiling rather than a starting point for refractory patients. She is explicit that for patients who tolerate 100 U well but achieve only modest or short-lived improvement, escalation to 200 U is an evidence-based option supported by the NIH-funded ROSETTA study, which demonstrated durable, satisfying improvement in refractory urgency incontinence at the higher dose, with a prolonged effect lasting into the 7-month range. She is equally explicit that this constitutes off-label use in idiopathic OAB, documents the conversation accordingly, and initiates a financial discussion upfront: the additional 100 U may not be covered by insurance, and the out-of-pocket cost could exceed $1000—a reality she addresses directly rather than leaving patients to encounter it as a surprise.

Fosnight also reviews post-void residual (PVR) monitoring as an essential component of her onabotA workflow, both before injection and at the 2-week follow-up. Rather than applying a fixed PVR threshold as a binary inclusion or exclusion criterion, she investigates the clinical reason for an elevated PVR before drawing conclusions—considering factors such as constipation, suboptimal scan conditions, or detrusor hypocontractility—and repeats the measurement as needed to establish a reliable baseline. When elevated PVR persists and a patient still wishes to proceed, she provides a clear risk estimate: Approximately 6% to 7% of patients receiving 100 U of onabotA on label require clean intermittent catheterization afterward, a figure that may climb to 10% to 12% in patients with pre-existing PVR elevation. She addresses dexterity limitations and caregiver availability as practical considerations when this risk is present. On long-term adherence, Fosnight notes that real-world data show approximately 79% of patients discontinuing onabotA—most not because they switched to another therapy, but because they lapsed from their retreatment schedule. Her response is systematic: All follow-up and retreatment appointments are scheduled in advance, her practice maintains an open schedule extending at least 18 months forward, and front-desk staff understand that appointment continuity is a clinical priority.